12 August 2020 - NICE has published its final guidance on the use of brentuximab vedotin in combination with chemotherapy for untreated systemic anaplastic large cell lymphoma.

Brentuximab vedotin with cyclophosphamide, doxorubicin and prednisone is recommended, within its marketing authorisation, as an option for untreated systemic anaplastic large cell lymphoma in adults. 

It is only recommended if Takeda provides brentuximab vedotin according to the commercial arrangement.

Read NICE technology appraisal guidance for brentuximab vedotin